{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:35:21Z","timestamp":1781624121311,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T00:00:00Z","timestamp":1636156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T00:00:00Z","timestamp":1636156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Antimicrob Resist Infect Control"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Antimicrobial stewardship (AMS) strategies worldwide focus on optimising the use of antibiotics. Selective susceptibility reporting is recommended as an effective AMS tool although there is a lack of representative studies investigating the impact of selective susceptibility reporting on antibiotic use. The aim of this study was to investigate the impact of selective susceptibility reporting of <jats:italic>Staphylococcus aureus <\/jats:italic>(<jats:italic>S. aureus<\/jats:italic>) on antibiotic consumption. Enhancing the use of narrow-spectrum beta-lactam antibiotics such as flucloxacillin\/cefazolin\/cefalexin is one of the main goals in optimising antibiotic therapy of <jats:italic>S. aureus<\/jats:italic> infections.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This interventional study with control group was conducted at a tertiary care hospital in Germany. During the one-year interventional period susceptibility reports for all methicillin-sensitive <jats:italic>S. aureus<\/jats:italic> (MSSA) were restricted to flucloxacillin\/cefazolin\/cefalexin, trimethoprim-sulfamethoxazole, clindamycin, gentamicin and rifampin\/fosfomycin, instead of reporting all tested antibiotics. The impact of implementing selective reporting was analysed by monitoring total monthly antibiotic consumption in our hospital and in a reference hospital (recommended daily dose\/100 occupied bed days: RDD\/100 BD), as well as on an individual patient level by analysing days of therapy adjusted for bed days (DOT\/ 100 BD) for patients with <jats:italic>S. aureus<\/jats:italic> bacteremia (SAB) and respectively skin and soft tissue infections (SSTI).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>MSSA-antibiograms were acquired for 2836 patients. The total use of narrow-spectrum beta-lactams more than doubled after implementing selective reporting (from 1.2 to 2.8 RDD\/100 BD, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). The use of intravenous flucloxacillin\/cefazolin for SAB rose significantly from 52 to 75 DOT\/100 BD (plus 42%), just as the use of oral cefalexin for SSTI (from 1.4 to 9.4 DOT\/100 BD, from 3 to 17 of 85\/88 patients). Considering the overall consumption, there was no decrease in antibiotics omitted from the antibiogram. This was probably due to their wide use for other infections.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>As narrow-spectrum beta-lactams are not widely used for other infections, their increase in the overall consumption of the entire hospital was a strong indicator that selective reporting guided clinicians to an optimised antibiotic therapy of <jats:italic>S. aureus<\/jats:italic> infections. On a patient level, this assumption was verified by a significant improved treatment of <jats:italic>S. aureus<\/jats:italic> infections in the subgroups of SAB and SSTI. As useful AMS tool, we recommend implementing selective reporting rules into the national\/international standards for susceptibility reporting.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13756-021-01021-7","type":"journal-article","created":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T18:02:26Z","timestamp":1636221746000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Staphylococcus aureus\u00a0- selective reporting of antibiogram results and its impact on antibiotic use:\u00a0Interventional study with a reference group on the effect of switching from non-selective to selective antibiotic reporting"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7416-1451","authenticated-orcid":false,"given":"Franka","family":"Lestin-Bernstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Harberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Schumacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Briedigkeit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Heese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Biedermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,6]]},"reference":[{"key":"1021_CR1","unstructured":"European Centre for Disease Prevention and Control. Proposals for EU guidelines on the prudent use of antimicrobials in humans. Stockholm: ECDC; 2017."},{"key":"1021_CR2","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1093\/cid\/ciw118","volume":"62","author":"TF Barlam","year":"2016","unstructured":"Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, et al. Implementing an antibiotic stewardship program: guidelines by the infectious diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Inf Dis. 2016;62:e51\u201377.","journal-title":"Clin Inf Dis"},{"key":"1021_CR3","unstructured":"de With K, Wilke K, Kern WV, Strau\u00df R, Kramme E, Friedrichs A, et al. S3- Leitlinie Strategien zur Sicherung rationaler Antibiotika-Anwendung im Krankenhaus. AWMF-Registernummer 092\/001\u2014update 2018"},{"key":"1021_CR4","doi-asserted-by":"crossref","unstructured":"Allerberger F, Lechner A, Wechsler-F\u00f6rd\u00f6s A, Gareis R on behalf of ABS International. Optimization of antibiotic use in hospitals\u2014Antimicrobial Stewardship and the EU Project ABS International. Chemotherapy. 2008;54:260\u2013267.","DOI":"10.1159\/000149716"},{"key":"1021_CR5","doi-asserted-by":"crossref","unstructured":"Howard P, Pulcini C, Levy Hara G, West RM, Gould IM, Harbarth S, Nathwani D; ESCMID Study Group for Antimicrobial Policies (ESGAP); ISC Group on Antimicrobial Stewardship. An international cross-sectional survey of antimicrobial stewardship programmes in hospitals. J Antimicrob Chemother. 2015;70:1245\u201355.","DOI":"10.1093\/jac\/dku497"},{"key":"1021_CR6","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S1473-3099(16)00065-7","volume":"16","author":"EC Schuts","year":"2016","unstructured":"Schuts EC, Hulscher MEJL, Mouton JW, Verduin CM, Stuart JWTC, Overdiek HWPM, et al. Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16:847\u201356.","journal-title":"Lancet Infect Dis"},{"key":"1021_CR7","doi-asserted-by":"crossref","unstructured":"Osthoff M, Bielicki J, Widmer AF, For Swissnoso. Evaluation of existing and desired antimicrobial stewardship activities and strategies in Swiss hospitals. Swiss Med Wkly. 2017; 147:w14512.","DOI":"10.4414\/smw.2017.14512"},{"key":"1021_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0924-8579(99)00144-2","volume":"14","author":"RJ Cunney","year":"2000","unstructured":"Cunney RJ, Smyth EG. The impact of laboratory reporting practice on antibiotic utilization. Int J Antimicrob Agents. 2000;14:13\u20139.","journal-title":"Int J Antimicrob Agents"},{"key":"1021_CR9","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1093\/jac\/dkr137","volume":"66","author":"R Kaki","year":"2011","unstructured":"Kaki R, Elligsen M, Walker S, Simor A, Palmay L, Daneman N. Impact of antimicrobial stewardship in critical care: a systematic review. J Antimicrob Chemother. 2011;66:1223\u201330.","journal-title":"J Antimicrob Chemother"},{"key":"1021_CR10","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1086\/510393","volume":"44","author":"TH Dellit","year":"2007","unstructured":"Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship. Clin Inf Dis. 2007;44:159\u201377.","journal-title":"Clin Inf Dis"},{"key":"1021_CR11","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1128\/CMR.00066-16","volume":"30","author":"P Morency-Potvin","year":"2017","unstructured":"Morency-Potvin P, Schwartz DN, Weinstein RA. Antimicrobial Stewardship: how the microbiology laboratory can right the ship. Clin Microbiol Rev. 2017;30:381\u2013407.","journal-title":"Clin Microbiol Rev"},{"key":"1021_CR12","unstructured":"Duguid M, Cruickshank, M. Antimicrobial stewardship in Australian hospitals 2011. Available from https:\/\/www.savetyandqualitiy.gov.au\/wp-content\/uplouds\/2011\/01\/Antimicrobioal-stewardship-in-Australian-hospitals-2011.pdf"},{"key":"1021_CR13","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/jac\/dkt108","volume":"68","author":"JL Nissen","year":"2013","unstructured":"Nissen JL, Skov R, Knudsen JD, Ostergaard C, Sch\u00f8nheyder HC, Frimodt-M\u00f8ller N, Benfield T. Effectiveness of penicillin, dicloxacillin and cefuroxime for penicillin-susceptible Staphylococcus aureus bacteremia: a retrospective, propensity-score-adjusted case-control and cohort analysis. J Antimicrob Chemother. 2013;68:1894\u2013900.","journal-title":"J Antimicrob Chemother"},{"key":"1021_CR14","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1111\/j.1469-0691.2010.03425.x","volume":"17","author":"M Paul","year":"2011","unstructured":"Paul M, Zemer-Wassercug N, Talker O, Lishtzinsky Y, Lev B, Samra Z, Leibovici L, Bishara J. Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteremia? Clin Microbiol Infect. 2011;17:1581\u20136.","journal-title":"Clin Microbiol Infect"},{"key":"1021_CR15","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s00063-017-0270-4","volume":"112","author":"S Weis","year":"2017","unstructured":"Weis S, Kimmig A, Hagel S, Pletz MW. Antibiotic Stewardship am Beispiel der Staphylococcus aureus Bakteri\u00e4mie. Med Klin Intensivmed Notfmed. 2017;112:192\u20138.","journal-title":"Med Klin Intensivmed Notfmed"},{"key":"1021_CR16","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1177\/1536867X1501500208","volume":"15","author":"A Linden","year":"2015","unstructured":"Linden A. Conducting interrupted time-series analysis for single- and multiple group comparisons. Stata J. 2015;15:480\u2013500.","journal-title":"Stata J"},{"key":"1021_CR17","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1086\/668429","volume":"33","author":"RL Jump","year":"2012","unstructured":"Jump RL, Olds DM, Seifi N, Kypriotakis G, Jury LA, Peron EP, et al. Effective antimicrobial stewardship in a long-term care facility through an infectious disease consultation service: keeping a LID on antibiotic use. Infect Control Hops Epidemiol. 2012;33:1185\u201392.","journal-title":"Infect Control Hops Epidemiol"},{"key":"1021_CR18","doi-asserted-by":"crossref","unstructured":"Rieg S1, Peyerl-Hoffmann G, de With K, Theilacker C, Wagner D, H\u00fcbner J, et al. Mortality of S. aureus bacteremia and infectious diseases specialist consultation: a study of 521 patients in Germany. J Infect. 2009;59:232\u20139.","DOI":"10.1016\/j.jinf.2009.07.015"},{"key":"1021_CR19","unstructured":"[PDF] Guidelines for Antimicrobial Stewardship in Hospitals in Irelandwww.hpsc.ie \u203a infectioncontrolandhai \u203a guidelines \u203a File,4116,enSARI Hospital Antimicrobial Stewardship Working Group. December 2009. Published on behalf of SARI by HSE Health Protection Surveillance Centre."},{"key":"1021_CR20","unstructured":"Svenska L\u00e4kares\u00e4llskapet. Refrensgruppen f\u00f6r antibiotikafragor. Available from: http:\/\/www.sls.se\/RAF\/. Accessed 06 Sept 2016."},{"key":"1021_CR21","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/jac\/dkg032","volume":"51","author":"TY Tan","year":"2003","unstructured":"Tan TY, McNulty C, Charlett A, Nessa N, Kelly C, Beswick T. Laboratory antibiotic susceptibility reporting and antibiotic prescribing in general practice. J Antimicrob Chemoth. 2003;51:379\u201384.","journal-title":"J Antimicrob Chemoth"},{"key":"1021_CR22","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1136\/jcp.39.2.233","volume":"39","author":"P Langdale","year":"1986","unstructured":"Langdale P, Millar ML. Influence of laboratory sensitivity reporting on antibiotic prescribing preferences of genereal practitioners in the Leeds area. J Clin Pathol. 1986;39:233\u20134.","journal-title":"J Clin Pathol"},{"key":"1021_CR23","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1093\/jac\/dkr088","volume":"66","author":"CA McNulty","year":"2011","unstructured":"McNulty CA, Lasseter GM, Charlett A, Lovering A, Howell-Jones R, Macgowan A, Thomas M. Does laboratory antibiotic susceptibility reporting influence primary care prescribing in urinary tract infection and other infections? J Antimicrob Chemother. 2011;66:1396\u2013404.","journal-title":"J Antimicrob Chemother"},{"key":"1021_CR24","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s10096-012-1786-4","volume":"32","author":"C Coupat","year":"2013","unstructured":"Coupat C, Pradier C, Degand N, Hofliger P, Pulcini C. Selective reporting of antibiotic susceptibility data improves the appropriateness of intended antibiotic prescriptions in urinary tract infections: a case-vignette randomised study. Eur J Clin Microbiol Infect Dis. 2013;32:627\u201336.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1021_CR25","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1128\/JCM.00950-16","volume":"54","author":"BJ Langford","year":"2016","unstructured":"Langford BJ, Seah J, Chan A, Downing M, Johnstone J, Matukas LM. Antimicrobial stewardship in the microbiology laboratory: Impact of selective susceptibility reporting on ciprofloxacin utilization and susceptibility of gram-negative isolates to ciprofloxacin in a hospital setting. J Clin Microbiol. 2016;54:2343\u20137.","journal-title":"J Clin Microbiol"},{"key":"1021_CR26","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1093\/jac\/40.4.595","volume":"40","author":"CH Steffee","year":"1997","unstructured":"Steffee CH, Morrell RM, Wasilauskas BL. Clinical use of rifampicin during routine reporting of rifampicin susceptibilities: a lesson in selective reporting of antimicrobial susceptibility data. J Antimicrob Chemother. 1997;40:595\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"1021_CR27","doi-asserted-by":"crossref","unstructured":"Pulcini C, Tebano G, Mutters NT, Tacconelli E, Cambau E, Kahlmeter G, Jarlier V. On behalf of the EUCIC-ESGAP-EUCAST Selective reporting Working Group. Selective reporting of antibiotic susceptibility test results in European countries: an ESCMID cross-sectional survey. Int J Antimicrob Agents 2017; 49: 162\u20136.","DOI":"10.1016\/j.ijantimicag.2016.11.014"},{"key":"1021_CR28","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1093\/jac\/dkl137","volume":"57","author":"D Nathwani","year":"2006","unstructured":"Nathwani D. Antimicrobial prescribing policy and practice in Scotland: recommendation for good antimicrobial practice in acute hospitals. J Antimicrob Chemother. 2006;57:1189\u201396.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 2","key":"1021_CR29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0195-6701(07)60019-X","volume":"65","author":"FM MacKenzie","year":"2007","unstructured":"MacKenzie FM, Gould IM, Bruce J, Mollison J, Monnet DL, Krcmery V, et al. The role of microbiology and pharmacy departments in the stewardship of antibiotic prescribing in European hospitals. J Hosp Infect. 2007;65(Suppl 2):73\u201381.","journal-title":"J Hosp Infect"},{"key":"1021_CR30","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1093\/jac\/dkq373","volume":"65","author":"M Paul","year":"2010","unstructured":"Paul M, Kariv G, Goldberg E, Raskin M, Shaked H, Hazzan R, et al. Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteremia. J Antimicrob Chemother. 2010;65:2658\u201365.","journal-title":"J Antimicrob Chemother"},{"key":"1021_CR31","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/1471-2334-11-279","volume":"11","author":"ML Schweizer","year":"2011","unstructured":"Schweizer ML, Furuno JP, Harris AD, Johnson JK, Shardell MD, McGregor JC, et al. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. BMC Infect Dis. 2011;11:279.","journal-title":"BMC Infect Dis"},{"key":"1021_CR32","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.ijantimicag.2016.09.007","volume":"48","author":"Z Weber","year":"2016","unstructured":"Weber Z, Ariano R, Lgace-Wiens P, Zelenitzky S. Multifaced antibiotic treatment analysis of methicillin-sensitive Staphylococcus aureus bloodstrean infections. J Antimicrob Agents. 2016;48:674\u20139.","journal-title":"J Antimicrob Agents"},{"key":"1021_CR33","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1128\/AAC.00700-07","volume":"52","author":"SH Kim","year":"2008","unstructured":"Kim SH, Kim KH, Kim HB, Kim NJ, Kim EC, Oh MD, Choe KW. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2008;52:192\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"1021_CR34","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1086\/510386","volume":"44","author":"ME Stryjewski","year":"2007","unstructured":"Stryjewski ME, Szczech LA, Benjamin DK Jr, Inrig JK, Kanafani ZA, Engemann JJ, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis. 2007;44:190\u20136.","journal-title":"Clin Infect Dis"},{"key":"1021_CR35","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/01.md.0000091184.93122.09","volume":"82","author":"FY Chang","year":"2003","unstructured":"Chang FY, Peacock JE Jr, Musher DM, Triplett P, MacDonald BB, Mylotte JM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore). 2003;82:333\u20139.","journal-title":"Medicine (Baltimore)"},{"key":"1021_CR36","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI document M100-S24. Wayne, PA: CLSI 2014."},{"key":"1021_CR37","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/antibiotics5010005","volume":"5","author":"MR Akpan","year":"2016","unstructured":"Akpan MR, Ahmad R, Shebl NA, Ashiru-Oredope D. A review of quality measures for assessing the impact of antimicrobial stewardship programs in hospitals. Antibiotics (Basel). 2016;5:5.","journal-title":"Antibiotics (Basel)"},{"key":"1021_CR38","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/jac\/dku560","volume":"70","author":"AD Bai","year":"2015","unstructured":"Bai AD, Showler A, Burry L, Steinberg M, Ricciuto DR, Fernandes T, et al. Comparative effectiveness of cefazolin versus cloxacillin as definitive antibiotic therapy for MSSA bacteremia: results from a large multicentre cohort study. J Antimicrob Chemother. 2015;70:1539\u201346.","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"1021_CR39","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1007\/s00134-018-5377-4","volume":"44","author":"C Fleischmann-Struzek","year":"2018","unstructured":"Fleischmann-Struzek C, Mikolajetz A, Schwarzkopf D, Cohen J, Hartog CS, Pletz M, et al. Challenges in assessing the burden of sepsis and understanding the inequalities of sepsis outcomes between National Health Systems: secular trends in sepsis and infection incidence and mortality in Germany. Intensive Care Med. 2018;44(11):1826\u201335.","journal-title":"Intensive Care Med"}],"container-title":["Antimicrobial Resistance &amp; Infection Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-021-01021-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13756-021-01021-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-021-01021-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T18:04:14Z","timestamp":1636221854000},"score":1,"resource":{"primary":{"URL":"https:\/\/aricjournal.biomedcentral.com\/articles\/10.1186\/s13756-021-01021-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,6]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1021"],"URL":"https:\/\/doi.org\/10.1186\/s13756-021-01021-7","relation":{},"ISSN":["2047-2994"],"issn-type":[{"value":"2047-2994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,6]]},"assertion":[{"value":"9 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the Faculty of Medicine at the University of Rostock (A 2017-0149) and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. The manuscript does not contain clinical studies or patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"157"}}